Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sipuleucel-T +/- Tasquinimod in mCRPC
NCT02159950Phase 2Completed
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Jan 2015
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tasquinimod in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoint: Change in Immune Response Assessed by IFN-g ELISPOT Specific for PA2024 up to 50 weeks. Started Jan 2015; status: completed.
02
Drugs
tasquinimod
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02159950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02159950.